文献速递神经外科与老年麻醉术前评估与围术期医学

瑞马唑仑与谵妄及认知功能的关联:随机对照试验的系统综述与荟萃分析

Association of remimazolam with delirium and cognitive function: A systematic review and meta-analysis of randomised controlled trials.
PubMed 文献 · Eur J Anaesthesiol · 2024-12-18

结果显示瑞马唑仑不增加谵妄发生率,且术后第7天MMSE评分优于对照组,但手术类型显著影响谵妄发生率。

要点

  • 瑞马唑仑与非苯二氮䓬类催眠药相比不增加谵妄发生率(OR=1.2,95%CI 0.76-1.91)。
  • 术后第1天和第3天MMSE评分两组无差异,第7天瑞马唑仑组更优。
  • 手术类型显著影响谵妄发生率。

核心结论

  • 瑞马唑仑与非苯二氮䓬类催眠药相比不增加谵妄发生率或认知功能障碍。
  • 瑞马唑仑与更好的短期术后认知功能相关。
  • 手术类型显著影响谵妄发生率。

研究设计与样本

  • 检索PubMed、Embase、Cochrane Library和Web of Science数据库至2024年4月27日。
  • 纳入标准为成年患者接受全身麻醉或镇静操作,使用瑞马唑仑作为主要催眠药或辅助用药,与其他催眠药或镇静药比较,评估认知功能或谵妄。

主要发现

  • 谵妄发生率在瑞马唑仑与其他镇静药之间无显著差异(n=3261;OR=1.2,95%CI 0.76-1.91;P=0.378843;I2=17%)。
  • 术后第1天MMSE评分两组无差异(n=263;平均差=0.60,95%CI -1.46-2.66;P=0.5684;I2=90%)。
  • 术后第3天MMSE评分两组无差异(n=163;平均差=1.33,95%CI -0.72-3.38;P=0.2028;I2=93%)。
  • 术后第7天MMSE评分瑞马唑仑组优于对照组(n=247;平均差=0.53,95%CI 0.30-0.75;P<0.0001;I2=28%)。

临床怎么用

  • 瑞马唑仑可用于全身麻醉或镇静,不增加谵妄风险。
  • 对于关注术后认知功能的患者,瑞马唑仑可能有利于第7天认知恢复。
  • 手术类型应纳入谵妄风险评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND STUDY OBJECTIVE: Delirium is an organic mental syndrome significantly associated with long-term cognitive decline, increased hospital stays and higher mortality. This systematic review of randomised controlled trials (RCTs) with meta-analysis assesses the association of remimazolam with postoperative cognitive function and delirium compared with non-benzodiazepine hypnotics. DESIGN: Systematic review of RCTs with meta-analysis. DATA SOURCES: PubMed, Embase, Cochrane Library and Web of Science databases up to 27 April 2024. ELIGIBILITY CRITERIA: Adult patients undergoing general anaesthesia or sedation procedures; use of remimazolam as the primary hypnotic or as an adjunct, administered via intermittent bolus or continuous infusion; comparison with other hypnotics or sedatives; evaluation of cognitive function or delirium. MAIN RESULTS: Twenty-three RCTs with 3598 patients were included. The incidence of delirium was not significantly different between remimazolam and other sedatives in general anaesthesia and sedation procedures [ n = 3261; odds ratio (OR) = 1.2, 95% confidence interval (CI), 0.76 to 1.91; P = 0.378843; I2 = 17%]. Regarding cognitive function evaluation, remimazolam showed no difference compared with the control group in Mini-Mental State Examination (MMSE) scores on the first postoperative day ( n = 263; mean difference = 0.60, 95% CI, -1.46 to 2.66; P = 0.5684; I2 = 90%) or on the third postoperative day ( n = 163; mean difference = 1.33, 95% CI, -0.72 to 3.38; P = 0.2028; I2 = 93%). Remimazolam exhibited superiority over the control group in MMSE scores on the seventh postoperative day ( n = 247; mean difference = 0.53, 95% CI, 0.30 to 0.75; P < 0.0001; I2 = 28%). CONCLUSION: Remimazolam does not increase the incidence of delirium or cognitive impairments compared with non-benzodiazepine hypnotics. However, the analysis showed that the type of surgery significantly influenced the incidence of delirium. Additionally, remimazolam was associated with better short-term postoperative cognitive function. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024532751.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Arias JA, Wegner GRM, Wegner BFM, et al. Association of remimazolam with delirium and cognitive function: A systematic review and meta-analysis of randomised controlled trials. Eur J Anaesthesiol. 2024. PMID: 39698854. doi:10.1097/EJA.0000000000002107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。